HIV-1 protease inhibitor ritonavir potentiates the effect of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of human myeloid leukemia cells via down-regulation of CYP24

被引:16
作者
Ikezoe, Takayuki
Bandobashi, Kentaro
Yang, Yang
Takeuchi, Eisho
Sekiguchi, Nobuo
Sakai, Shuichi
Koeffler, H. Phillip
Taguchi, Hirokuni
机构
[1] Kochi Univ, KMS, Dept Hematol & Resp Dis, Nankoku, Kochi 7838505, Japan
[2] Chugai Pharmaceut Co Ltd, Fuji Gotemba Res Labs, Shizuoka 4128513, Japan
[3] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Los Angeles, CA 90048 USA
基金
美国国家卫生研究院;
关键词
ritonavir; 1,25-dihydroxyvitamin D-3; 25-hydroxyvitamin D-3-24-hydroxylase (CYP24); myeloid leukemia; differentiation;
D O I
10.1016/j.leukres.2005.12.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
HIV-1 protease inhibitor, ritonavir (RTV) is a potent inhibitor of cytochrome p450 (CYPs) enzymes. This study explored the effects of RTV on CYP24 which converts 1,25-dihydroxyvitamin D-3 [1,25(OH)(2)D-3] to its inactive form 1,24,25,(OH)(3). Real-time RT-PCR showed that exposure of HL-60 cells to 1,25(OH)(2)D-3 induced expression of CYP24, and pre-incubation of these cells with RTV decreased this transcripts, resulting in increased intracellular levels of 1,25(OH)(2)D-3 and potentiation of the ability of 1,25(OH)(2)D-3 to induce growth arrest and differentiation of these cells. Taken together, inhibition of CYP24 might open a new paradigm for therapy using Vitamin D compounds. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1005 / 1011
页数:7
相关论文
共 29 条
[21]  
NORMAN AW, 1990, CANCER RES, V50, P6857
[22]   The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1) [J].
Olson, DP ;
Scadden, DT ;
D'Aquila, RT ;
De Pasquale, MP .
AIDS, 2002, 16 (13) :1743-1747
[23]   all-trans-retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia [J].
Ozpolat, B ;
Mehta, K ;
Tari, AM ;
Lopez-Berestein, G .
AMERICAN JOURNAL OF HEMATOLOGY, 2002, 70 (01) :39-47
[24]  
PEEHL DM, 1994, CANCER RES, V54, P805
[25]   ACTIONS OF VITAMIN-D-3 ANALOGS ON HUMAN PROSTATE-CANCER CELL-LINES - COMPARISON WITH 1,25-DIHYDROXYVITAMIN-D-3 [J].
SKOWRONSKI, RJ ;
PEEHL, DM ;
FELDMAN, D .
ENDOCRINOLOGY, 1995, 136 (01) :20-26
[26]   Inhibition of p38 MAP kinase activity up-regulates multiple MAP kinase pathways and potentiates 1,25-dihydroxyvitamin D3-induced differentiation of human leukemia HL60 cells [J].
Wang, XN ;
Rao, J ;
Studzinski, GP .
EXPERIMENTAL CELL RESEARCH, 2000, 258 (02) :425-437
[27]   c-Jun N-terminal kinase modulates 1,25-dihydroxyvitamin D3-induced cytochrome P450 3A4 gene expression [J].
Yasunami, Y ;
Hara, H ;
Iwamura, T ;
Kataoka, T ;
Adachi, T .
DRUG METABOLISM AND DISPOSITION, 2004, 32 (07) :685-688
[28]   Enhancement of antiproliferative activity of 1 alpha,25-dihydroxyvitamin D-3 (analogs) by cytochrome P450 enzyme inhibitors is compound- and cell-type specific [J].
Zhao, J ;
Tan, BK ;
Marcelis, S ;
Verstuyf, A ;
Bouillon, R .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1996, 57 (3-4) :197-202
[29]   1,25-DIHYDROXY-16-ENE-23-YNE-VITAMIN-D3 PROLONGS SURVIVAL-TIME OF LEUKEMIC MICE [J].
ZHOU, JY ;
NORMAN, AW ;
CHEN, DL ;
SUN, GW ;
USKOKOVIC, M ;
KOEFFLER, HP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (10) :3929-3932